ACCA: AI 评分 48/100 — AI 分析 (4月 2026)

Acacia Diversified Holdings, Inc. focuses on the extraction, processing, and distribution of medical-grade hemp oils and related products. The company operates in the niche market of high-CBD/low-THC botanicals and nutraceuticals.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

Acacia Diversified Holdings, Inc. operates in the specialty and generic drug manufacturing sector, focusing on high-CBD/low-THC medical-grade hemp oils. The company engages in extraction, processing, research, development, and distribution of medicinal hemp products and dietary supplements under the EUFLORIA brand, primarily within the United States.

ACCA是做什么的？

Acacia Diversified Holdings, Inc., formerly known as Acacia Automotive, Inc., was incorporated in 1984 and rebranded in October 2012 to focus on the burgeoning market for medical hemp products. Based in Clearwater, Florida, the company specializes in the extraction and processing of medical-grade hemp oils, characterized by their high cannabidiol (CBD) and low tetrahydrocannabinol (THC) content. These oils are derived from medical hemp plants cultivated within the United States. Acacia's business extends beyond mere extraction; it is actively involved in the research and development of botanicals endocannabinoid nutraceuticals. This includes the creation of a diverse product line aimed at addressing various health and wellness needs. The company also manages the retail and wholesale distribution of its medicinal hemp products and dietary supplements, ensuring accessibility to a broad consumer base. A key aspect of Acacia's distribution strategy involves its consumer products marketed under the EUFLORIA brand name, which are sold through multiple distribution channels. With a small team of 5 employees, Acacia operates with a lean structure, emphasizing innovation and market responsiveness in the rapidly evolving cannabis industry. The company's focus on high-quality CBD products positions it to capitalize on the increasing acceptance and demand for alternative health solutions.

ACCA的投资论点是什么？

Acacia Diversified Holdings, Inc. presents a speculative investment opportunity within the high-growth CBD market. The company's focus on medical-grade hemp oils and nutraceuticals aligns with increasing consumer interest in alternative health solutions. However, the company's negative profit margin of -329.4% and small market capitalization of $0.00B indicate significant financial challenges. Key value drivers include successful product development and expansion of distribution channels. Growth catalysts involve regulatory changes favoring CBD products and increased consumer acceptance. Potential risks include intense competition, regulatory uncertainty, and the company's ability to secure funding for ongoing operations and research.

ACCA在哪个行业运营？

Acacia Diversified Holdings, Inc. operates within the rapidly expanding market for specialty and generic drug manufacturers, specifically focusing on CBD-based products. The industry is characterized by increasing consumer demand for alternative health solutions and evolving regulatory landscapes. Competitors range from established pharmaceutical companies to smaller, specialized firms. The market is driven by factors such as the growing acceptance of cannabis-derived products for medicinal purposes and the increasing availability of CBD-based products through various retail channels. This competitive landscape requires companies like Acacia to differentiate themselves through product innovation, quality, and effective distribution strategies.

Drug Manufacturers - Specialty & Generic

Healthcare

ACCA有哪些增长机遇？

Expansion of EUFLORIA Product Line: Acacia has the opportunity to expand its EUFLORIA brand product line to include a wider range of CBD-infused products, targeting various consumer needs such as skincare, pain relief, and sleep aids. The global CBD skincare market is projected to reach $3.48 billion by 2028, presenting a significant growth avenue. Successful product diversification and marketing could drive increased revenue and brand recognition for Acacia.
Strategic Partnerships with Retailers: Forming strategic partnerships with established retailers, both online and brick-and-mortar, can significantly expand Acacia's distribution network. Collaborating with major health and wellness retailers or specialty CBD stores can provide access to a broader customer base and increase product visibility. The timeline for establishing such partnerships is estimated at 12-18 months, with potential revenue impact within 2-3 years.
Geographic Expansion within the United States: Acacia can focus on expanding its operations to new states within the United States, particularly those with favorable regulatory environments for CBD products. Targeting states with high population densities and a growing interest in alternative health solutions can drive revenue growth. This expansion strategy could be implemented within the next 24 months, with potential revenue gains within 3-5 years.
Research and Development of Novel CBD Formulations: Investing in research and development to create novel CBD formulations and delivery methods can provide a competitive edge. Developing innovative products such as fast-acting CBD patches, sublingual sprays, or enhanced bioavailability capsules can attract consumers seeking more effective and convenient solutions. The timeline for R&D and product development is estimated at 2-3 years, with potential market introduction within 3-5 years.
Capitalizing on Regulatory Changes: Monitoring and adapting to evolving regulatory changes in the CBD industry is crucial for growth. As regulations become more standardized and favorable, Acacia can capitalize on opportunities such as expanding into new markets, developing new products, and establishing partnerships with larger pharmaceutical companies. The timeline for regulatory changes is uncertain, but proactive adaptation can provide a significant competitive advantage.

Acacia Diversified Holdings, Inc. operates in the high-growth CBD market, focusing on medical-grade hemp oils.
The company's gross margin is 4.9%, indicating potential challenges in profitability.
Acacia's profit margin is -329.4%, reflecting significant losses.
The company has a small team of 5 employees, suggesting a lean operational structure.
Acacia's beta of -0.55 suggests a negative correlation with the broader market.

ACCA提供哪些产品和服务？

Extracts and processes high-CBD/low-THC content medical grade hemp oils.
Conducts research and development of botanicals endocannabinoid nutraceuticals.
Engages in retail and wholesale distribution of medicinal hemp products.
Offers dietary supplements.
Markets consumer products under the EUFLORIA brand name.
Focuses on distribution through various channels.

ACCA如何赚钱？

Extraction and processing of medical-grade hemp oils.
Research and development of CBD-based products.
Sales of medicinal hemp products and dietary supplements through retail and wholesale channels.

Individuals seeking alternative health and wellness solutions.
Retailers and wholesalers in the health and wellness industry.
Consumers interested in CBD-based products for various health conditions.

Proprietary extraction and processing techniques for high-CBD hemp oils.
Established brand presence with the EUFLORIA product line.
Focus on research and development of innovative CBD formulations.

什么因素可能推动ACCA股价上涨？

Upcoming: Potential regulatory changes favoring CBD products could expand market access.
Ongoing: Increasing consumer acceptance of CBD for health and wellness purposes.
Ongoing: Expansion of distribution channels through strategic partnerships.
Upcoming: Successful development and launch of new CBD-based products.

ACCA的主要风险是什么？

Potential: Intense competition in the rapidly growing CBD market.
Ongoing: Regulatory uncertainty surrounding CBD products and their distribution.
Potential: Challenges in securing funding for ongoing operations and research.
Ongoing: Fluctuations in the price and availability of hemp.
Potential: Negative profit margin and limited financial resources.

ACCA的核心优势是什么？

Focus on high-CBD/low-THC medical grade hemp oils.
Involvement in research and development of botanicals endocannabinoid nutraceuticals.
Retail and wholesale distribution of medicinal hemp products.
Consumer products offered under the EUFLORIA brand.

ACCA的劣势是什么？

Negative profit margin of -329.4%.
Small market capitalization of $0.00B.
Limited number of employees (5).
Dependence on the evolving regulatory environment for CBD products.

ACCA有哪些机遇？

Expansion of the EUFLORIA product line.
Strategic partnerships with retailers.
Geographic expansion within the United States.
Research and development of novel CBD formulations.

ACCA面临哪些威胁？

Intense competition in the CBD market.
Regulatory uncertainty surrounding CBD products.
Potential challenges in securing funding for ongoing operations.
Fluctuations in the price and availability of hemp.

ACCA的竞争对手是谁？

American Bio Medica Corporation — Focuses on developing and marketing cost-effective immunoassay test kits. — (ABMC)
Allied Healthcare Products, Inc. — Manufactures and supplies respiratory therapy equipment. — (AHPIQ)
CRISPR Medicine Innovation Co., Ltd. — Focuses on discovering and developing gene-editing therapies. — (CRXM)
Cryo-Cell International, Inc. — Specializes in preserving stem cells from umbilical cord blood. — (CRYO)
DMC Global Inc. — Provides technical products and services to the energy, industrial, and infrastructure markets. — (DMTKQ)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Jeffery D. Bearden
Headquarters: Clearwater, US
Employees: 5
Founded: 2010

AI Insight

AI analysis pending for ACCA

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Acacia Diversified Holdings, Inc. do?

Acacia Diversified Holdings, Inc. specializes in the extraction, processing, and distribution of medical-grade hemp oils with high CBD and low THC content. The company is also involved in the research and development of botanicals endocannabinoid nutraceuticals, offering a range of medicinal hemp products and dietary supplements. Its consumer products are marketed under the EUFLORIA brand, targeting health and wellness markets through various distribution channels. The company operates within the specialty and generic drug manufacturing sector, focusing specifically on CBD-based products.

What do analysts say about ACCA stock?

As of 2026-03-16, there is no available analyst coverage for Acacia Diversified Holdings, Inc. due to its OTC listing and small market capitalization. Key valuation metrics such as price-to-earnings ratio are not meaningful due to negative earnings. Growth considerations include the company's ability to expand its product line, secure funding, and navigate the evolving regulatory landscape for CBD products. Investors should conduct their own thorough research and consider the inherent risks associated with investing in OTC-listed companies.

What are the main risks for ACCA?

The main risks for Acacia Diversified Holdings, Inc. include intense competition in the CBD market, regulatory uncertainty surrounding CBD products, and challenges in securing funding for ongoing operations. The company's negative profit margin and small market capitalization also pose significant financial risks. Additionally, fluctuations in the price and availability of hemp could impact production costs and profitability. Investors should carefully consider these risks before investing in ACCA.